<DOC>
	<DOCNO>NCT01684852</DOCNO>
	<brief_summary>This comparative , open label , parallel group , non interventional study demonstrate efficacy tolerability BAT04 . In addition efficacy safety shall compare Hyaluronic acid ( HA ) -Product . The patient applies BAT04 HA-Product accord instruction use six time daily eye period 28 day . Response treatment record day 28 .</brief_summary>
	<brief_title>Non Interventional Study Evaluate Efficacy Tolerability Ectoin Containing Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male female person age 18 year Demonstrated mild moderate keratoconjunctivitis sicca ( `` dry eye '' ) Acute symptoms dry eye : DEWS 13 tear breakup time TBUT &lt; 10 agreement abide routinely provide doctor 's appointment followup ( reflect plan visit observation plan resist ) inflammation anterior segment trauma Contact lens wearer Any disease , opinion treat physician affect outcome study . Patients know intolerance one substance use Surgical procedure eye last 6 week inclusion trial patient addictive disorder substance abuse fallow past 12 month , well person incapable give consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>dry eye , sicca , HA , Hyaluronic Acid , ectoin , ectoine , bitop</keyword>
</DOC>